Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 2/2007

01-06-2007 | Review

The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal–maternal interface

Authors: Paola Viganò, Marcella Cintorino, Frederick Schatz, Charles J. Lockwood, Felice Arcuri

Published in: Seminars in Immunopathology | Issue 2/2007

Login to get access

Abstract

Macrophage migration inhibitory factor (MIF) is a pivotal regulator of the innate and adaptive immunity affecting the response and behavior of macrophages and lymphocytes. MIF is also implicated in other fundamental cellular processes including angiogenesis and cell proliferation. Several studies examined the expression of MIF in reproductive organs and tissues and its involvement in different aspects of human and animal reproduction. The goal of this review was to summarize these findings and discuss, in particular, the role of MIF in the maintenance of the immune privilege at the human fetal–maternal interface.
Literature
1.
George M, Vaughan JH (1962) In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med 111:514–521PubMed
2.
Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82PubMed
3.
David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell–ntigen interaction. Proc Natl Acad Sci USA 56:72–77PubMed
4.
Churchill WH Jr, Piessens WF, Sulis CA, David JR (1975) Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol 115:781–786PubMed
5.
Nathan CF, Remold HG, David JR (1973) Characterization of a lymphocyte factor which alters macrophage functions. J Exp Med 137:275–290PubMed
6.
Paralkar V, Wistow G (1994) Cloning the human gene for macrophage migration inhibitory factor (MIF). Genomics 19:48–51PubMed
7.
Budarf M, McDonald T, Sellinger B, Kozak C, Graham C, Wistow G (1997) Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. Genomics 39:235–236PubMed
8.
Bozza M, Kolakowski LF Jr, Jenkins NA, Gilbert DJ, Copeland NG, David JR, Gerard C (1995) Structural characterization and chromosomal location of the mouse macrophage migration inhibitory factor gene and pseudogenes. Genomics 27:412–419PubMed
9.
Mitchell R, Bacher M, Bernhagen J, Pushkarskaya T, Seldin MF, Bucala R (1995) Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 154:3863–3870PubMed
10.
Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800PubMed
11.
Magi B, Bini L, Liberatori S, Marzocchi B, Raggiaschi R, Arcuri F, Tripodi SA, Cintorino M, Tosi P, Pallini V (1998) Charge heterogeneity of macrophage migration inhibitory factor (MIF) in human liver and breast tissue. Electrophoresis 19:2010–2013PubMed
12.
Suzuki M, Sugimoto H, Nakagawa A, Tanaka I, Nishihira J, Sakai M (1996) Crystal structure of the macrophage migration inhibitory factor from rat liver. Nat Struct Biol 3:259–266PubMed
13.
Sun HW, Bernhagen J, Bucala R, Lolis E (1996) Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 93:5191–5196PubMed
14.
Blocki FA, Schlievert PM, Wackett LP (1992) Rat liver protein linking chemical and immunological detoxification systems. Nature 360:269–270PubMed
15.
Nishihira J, Kuriyama T, Nishino H, Ishibashi T, Sakai M, Nishi S (1993) Purification and characterization of human macrophage migration inhibitory factor: evidence for specific binding to glutathione and formation of subunit structure. Biochem Mol Biol Int 31:841–850PubMed
16.
Sun HW, Swope M, Cinquina C, Bedarkar S, Bernhagen J, Bucala R, Lolis E (1996) The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng 9:631–635PubMed
17.
Mischke R, Kleemann R, Brunner H, Bernhagen J (1998) Cross-linking and mutational analysis of the oligomerization state of the cytokine macrophage migration inhibitory factor (MIF). FEBS Lett 427:85–90PubMed
18.
Philo JS, Yang TH, LaBarre M (2004) Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys Chem 108:77–87PubMed
19.
Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467–1476PubMed
20.
Beswick EJ, Pinchuk IV, Suarez G, Sierra JC, Reyes VE (2006) Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol 176:6794–6801PubMed
21.
Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 177:8730–8739PubMed
22.
Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595–606PubMed
23.
Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341–346PubMed
24.
Bernhagen J, Bacher M, Calandra T, Metz CN, Doty SB, Donnelly T, Bucala R (1996) An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 183:277–282PubMed
25.
Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMed
26.
Kleemann R, Kapurniotu A, Frank RW, Gessner A, Mischke R, Flieger O, Juttner S, Brunner H, Bernhagen J (1998) Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 280:85–102PubMed
27.
Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M, Sanchez JC, Frutiger S, Hughes G, Pallini V, Hochstrasser DF, Tosi P (1997) Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 18:2832–2841PubMed
28.
Meyer-Siegler K, Hudson PB (1996) Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48:448–452PubMed
29.
del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, Cintorino M (2000) Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate 45:51–57PubMed
30.
Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R (1999) An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5:181–191PubMed
31.
White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9:853–860PubMed
32.
Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J (1999) High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264:751–758PubMed
33.
Nishihira J (1998) Novel pathophysiological aspects of macrophage migration inhibitory factor (review). Int J Mol Med 2:17–28PubMed
34.
Baugh JA, Bucala R (2002) Macrophage migration inhibitory factor. Crit Care Med 30:S27–S35
35.
Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4:449–460PubMed
36.
Mitchell RA (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal 16:13–19PubMed
37.
Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMed
38.
Calandra T, Spiegel LA, Metz CN, Bucala R (1998) Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA 95:11383–11388PubMed
39.
Abe R, Peng T, Sailors J, Bucala R, Metz CN (2001) Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 166:747–753PubMed
40.
Yan X, Orentas RJ, Johnson BD (2006) Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine 33:188–198PubMed
41.
Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756–759PubMed
42.
Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, Calandra T, Gemsa D, Donnelly T, Atkins RC, Bucala R (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150:235–246PubMed
43.
Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164–170PubMed
44.
Lind M, Trindade MC, Nakashima Y, Schurman DJ, Goodman SB, Smith L (1999) Chemotaxis and activation of particle-challenged human monocytes in response to monocyte migration inhibitory factor and C-C chemokines. J Biomed Mater Res 48:246–250PubMed
45.
Hermanowski-Vosatka A, Mundt SS, Ayala JM, Goyal S, Hanlon WA, Czerwinski RM, Wright SD, Whitman CP (1999) Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry 38:12841–12849PubMed
46.
Gregory JL, Morand EF, McKeown SJ, Ralph JA, Hall P, Yang YH, McColl SR, Hickey MJ (2006) Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 177:8072–8079PubMed
47.
Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895–1902PubMed
48.
Roger T, David J, Glauser MP, Calandra T (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414:920–924PubMed
49.
Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira J (1997) Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion. Immunology 92:131–137PubMed
50.
Juttner S, Bernhagen J, Metz CN, Rollinghoff M, Bucala R, Gessner A (1998) Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol 161:2383–2390PubMed
51.
Pozzi LA, Weiser WY (1992) Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells. Cell Immunol 145:372–379PubMed
52.
Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71PubMed
53.
Daun JM, Cannon JG (2000) Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkappaBalpha. Am J Physiol Regul Integr Comp Physiol 279:R1043–R1049PubMed
54.
Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY (1998) Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160:5693–5696PubMed
55.
Repp AC, Mayhew ES, Apte S, Niederkorn JY (2000) Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 165:710–715PubMed
56.
Arcuri F, Cintorino M, Carducci A, Papa S, Riparbelli MG, Mangioni S, Di Blasio AM, Tosi P, Vigano P (2006) Human decidual natural killer cells as a source and target of macrophage migration inhibitory factor. Reproduction 131:175–182PubMed
57.
Esumi N, Budarf M, Ciccarelli L, Sellinger B, Kozak CA, Wistow G (1998) Conserved gene structure and genomic linkage for d-dopachrome tautomerase (DDT) and MIF. Mamm Genome 9:753–757PubMed
58.
Rosengren E, Bucala R, Aman P, Jacobsson L, Odh G, Metz CN, Rorsman H (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2:143–149PubMed
59.
Rosengren E, Aman P, Thelin S, Hansson C, Ahlfors S, Bjork P, Jacobsson L, Rorsman H (1997) The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417:85–88PubMed
60.
Matsunaga J, Sinha D, Pannell L, Santis C, Solano F, Wistow GJ, Hearing VJ (1999) Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J Biol Chem 274:3268–3271PubMed
61.
Bendrat K, Al-Abed Y, Callaway DJ, Peng T, Calandra T, Metz CN, Bucala R (1997) Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 36:15356–15362PubMed
62.
Mischke R, Gessner A, Kapurniotu A, Juttner S, Kleemann R, Brunner H, Bernhagen J (1997) Structure activity studies of the cytokine macrophage migration inhibitory factor (MIF) reveal a critical role for its carboxy terminus. FEBS Lett 414:226–232PubMed
63.
Wen Y, Li GW, Bekhor I (1996) Lens epithelial cell mRNA. III. Elevated expression of macrophage migration inhibitory factor mRNA in galactose cataracts. Curr Eye Res 15:125–130PubMed
64.
Mitchell RA, Metz CN, Peng T, Bucala R (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274:18100–18106PubMed
65.
Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408:211–216PubMed
66.
Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 4:707–714PubMed
67.
Ren Y, Chan HM, Fan J, Xie Y, Chen YX, Li W, Jiang GP, Liu Q, Meinhardt A, Tam PK (2006) Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene 25:3501–3508PubMed
68.
Ogawa H, Nishihira J, Sato Y, Kondo M, Takahashi N, Oshima T, Todo S (2000) An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12:309–314PubMed
69.
Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST (2003) Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107:22–29PubMed
70.
Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A, Nagasue N (2005) Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 103:588–598PubMed
71.
Shun CT, Lin JT, Huang SP, Lin MT, Wu MS (2005) Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas. World J Gastroenterol 11:3767–3771PubMed
72.
Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, Wong J (2005) Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242:55–63PubMed
73.
Yang Y, Degranpre P, Kharfi A, Akoum A (2000) Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. J Clin Endocrinol Metab 85:4721–4727PubMed
74.
Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, Calandra T, Bucala R, Bernhagen J (2006) Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 18:688–703PubMed
75.
Aeberli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF (2006) Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett 580:974–981PubMed
76.
Amin MA, Haas CS, Zhu K, Mansfield PJ, Kim MJ, Lackowski NP, Koch AE (2006) Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 107:2252–2261PubMed
77.
Lacey D, Sampey A, Mitchell R, Bucala R, Santos L, Leech M, Morand E (2003) Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 48:103–109PubMed
78.
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375–1382PubMed
79.
Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 99:345–350PubMed
80.
Petrenko O, Fingerle-Rowson G, Peng T, Mitchell RA, Metz CN (2003) Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J Biol Chem 278:11078–11085PubMed
81.
Petrenko O, Moll UM (2005) Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 17:225–236PubMed
82.
Claret FX, Hibi M, Dhut S, Toda T, Karin M (1996) A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383:453–457PubMed
83.
Deng XW, Dubiel W, Wei N, Hofmann K, Mundt K, Colicelli J, Kato J, Naumann M, Segal D, Seeger M, Carr A, Glickman M, Chamovitz DA (2000) Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet 16:202–203PubMed
84.
Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131–E136PubMed
85.
Tomoda K, Kubota Y, Kato J (1999) Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398:160–165PubMed
86.
Suzuki H, Kanagawa H, Nishihira J (1996) Evidence for the presence of macrophage migration inhibitory factor in murine reproductive organs and early embryos. Immunol Lett 51:141–147PubMed
87.
Wada S, Fujimoto S, Mizue Y, Nishihira J (1997) Macrophage migration inhibitory factor in the human ovary: presence in the follicular fluids and production by granulosa cells. Biochem Mol Biol Int 41:805–814PubMed
88.
Matsuura T, Sugimura M, Iwaki T, Ohashi R, Kanayama N, Nishihira J (2002) Anti-macrophage inhibitory factor antibody inhibits PMSG-hCG-induced follicular growth and ovulation in mice. J Assist Reprod Genet 19:591–595PubMed
89.
Bove SE, Petroff MG, Nishibori M, Pate JL (2000) Macrophage migration inhibitory factor in the bovine corpus luteum: characterization of steady-state messenger ribonucleic acid and immunohistochemical localization. Biol Reprod 62:879–885PubMed
90.
Arcuri F, Ricci C, Ietta F, Cintorino M, Tripodi SA, Cetin I, Garzia E, Schatz F, Klemi P, Santopietro R, Paulesu L (2001) Macrophage migration inhibitory factor in the human endometrium: expression and localization during the menstrual cycle and early pregnancy. Biol Reprod 64:1200–1205PubMed
91.
Kats R, Al-Akoum M, Guay S, Metz C, Akoum A (2005) Cycle-dependent expression of macrophage migration inhibitory factor in the human endometrium. Hum Reprod 20:3518–3525PubMed
92.
Paulesu L, Cateni C, Romagnoli R, Ietta F, Dantzer V (2005) Variation in macrophage-migration-inhibitory-factor immunoreactivity during porcine gestation. Biol Reprod 72:949–953PubMed
93.
Wang B, Goff AK (2003) Interferon-tau stimulates secretion of macrophage migration inhibitory factor from bovine endometrial epithelial cells. Biol Reprod 69:1690–1696PubMed
94.
Akoum A, Metz CN, Morin M (2005) Marked increase in macrophage migration inhibitory factor synthesis and secretion in human endometrial cells in response to human chorionic gonadotropin hormone. J Clin Endocrinol Metab 90:2904–2910PubMed
95.
Cao WG, Morin M, Metz C, Maheux R, Akoum A (2005) Stimulation of macrophage migration inhibitory factor expression in endometrial stromal cells by interleukin 1, beta involving the nuclear transcription factor NFkappaB. Biol Reprod 73:565–570PubMed
96.
Cao WG, Morin M, Sengers V, Metz C, Roger T, Maheux R, Akoum A (2006) Tumour necrosis factor-alpha up-regulates macrophage migration inhibitory factor expression in endometrial stromal cells via the nuclear transcription factor NF-kappaB. Hum Reprod 21:421–428PubMed
97.
Schaefer TM, Fahey JV, Wright JA, Wira CR (2005) Migration inhibitory factor secretion by polarized uterine epithelial cells is enhanced in response to the TLR3 agonist poly (I:C). Am J Reprod Immunol 54:193–202PubMed
98.
Arcuri F, Buchwalder L, Toti P, Cintorino M, Tosi P, Lockwood CJ, Rybalov B, Schatz F (2007) Differential regulation of colony stimulating factor 1 and macrophage migration inhibitory factor expression by inflammatory cytokines in term human decidua: implications for macrophage trafficking at the fetal-maternal interface. Biol Reprod 76:433–439PubMed
99.
Lockwood CJ, Matta P, Krikun G, Koopman LA, Masch R, Toti P, Arcuri F, Huang ST, Funai EF, Schatz F (2006) Regulation of monocyte chemoattractant protein-1 expression by tumor necrosis factor-alpha and interleukin-1beta in first trimester human decidual cells: implications for preeclampsia. Am J Pathol 168:445–452PubMed
100.
Lockwood CJ, Arcuri F, Toti P, Felice CD, Krikun G, Guller S, Buchwalder LF, Schatz F (2006) Tumor necrosis factor-alpha and interleukin-1beta regulate interleukin-8 expression in third trimester decidual cells: implications for the genesis of chorioamnionitis. Am J Pathol 169:1294–1302PubMed
101.
Zeng FY, Weiser WY, Kratzin H, Stahl B, Karas M, Gabius HJ (1993) The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor. Arch Biochem Biophys 303:74–80PubMed
102.
Arcuri F, Cintorino M, Vatti R, Carducci A, Liberatori S, Paulesu L (1999) Expression of macrophage migration inhibitory factor transcript and protein by first-trimester human trophoblasts. Biol Reprod 60:1299–1303PubMed
103.
Ietta F, Todros T, Ticconi C, Piccoli E, Zicari A, Piccione E, Paulesu L (2002) Macrophage migration inhibitory factor in human pregnancy and labor. Am J Reprod Immunol 48:404–409PubMed
104.
Chaiworapongsa T, Romero R, Espinoza J, Kim YM, Edwin S, Bujold E, Gomez R, Kuivaniemi H (2005) Macrophage migration inhibitory factor in patients with preterm parturition and microbial invasion of the amniotic cavity. J Matern Fetal Neonatal Med 18:405–416PubMed
105.
Ietta F, Wu Y, Romagnoli R, Soleymanlou N, Orsini B, Zamudio S, Paulesu L, Caniggia I (2007) Oxygen regulation of macrophage migration inhibitory factor in human placenta. Am J Physiol Endocrinol Metab 292:E272–E280PubMed
106.
Zicari A, Ticconi C, Ietta F, Belmonte A, Bechi N, Realacci M, Di Vito M, Arcuri F, Russo M, Piccione E, Paulesu L (2006) Macrophage migration inhibitory factor-nitric oxide interaction in human fetal membranes at term pregnancy. J Soc Gynecol Investig 13:263–270PubMed
107.
Todros T, Bontempo S, Piccoli E, Ietta F, Romagnoli R, Biolcati M, Castellucci M, Paulesu L (2005) Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 123:162–166PubMed
108.
Yamada H, Kato EH, Morikawa M, Shimada S, Saito H, Watari M, Minakami H, Nishihira J (2003) Decreased serum levels of macrophage migration inhibition factor in miscarriages with normal chromosome karyotype. Hum Reprod 18:616–620PubMed
109.
Hristoskova S, Holzgreve W, Zhong XY, Hahn S (2006) Macrophage migration inhibition factor is elevated in pregnancy, but not to a greater extent in preeclampsia. Arch Gynecol Obstet 274:25–28PubMed
110.
Kats R, Metz CN, Akoum A (2002) Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. J Clin Endocrinol Metab 87:883–889PubMed
111.
Kats R, Collette T, Metz CN, Akoum A (2002) Marked elevation of macrophage migration inhibitory factor in the peritoneal fluid of women with endometriosis. Fertil Steril 78:69–76PubMed
112.
Morin M, Bellehumeur C, Therriault MJ, Metz C, Maheux R, Akoum A (2005) Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis. Fertil Steril 83:865–872PubMed
113.
Mahutte NG, Matalliotakis IM, Goumenou AG, Koumantakis GE, Vassiliadis S, Arici A (2004) Elevations in peritoneal fluid macrophage migration inhibitory factor are independent of the depth of invasion or stage of endometriosis. Fertil Steril 82:97–101PubMed
114.
Akoum A, Metz CN, Al-Akoum M, Kats R (2006) Macrophage migration inhibitory factor expression in the intrauterine endometrium of women with endometriosis varies with disease stage, infertility status, and pelvic pain. Fertil Steril 85:1379–1385PubMed
115.
Redman CW, Sacks GP, Sargent IL (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180:499–506PubMed
116.
Moffett-King A (2002) Natural killer cells and pregnancy. Nat Rev Immunol 2:656–663PubMed
117.
Kudo Y, Boyd CA, Spyropoulou I, Redman CW, Takikawa O, Katsuki T, Hara T, Ohama K, Sargent IL (2004) Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J Reprod Immunol 61:87–98PubMed
118.
Girardi G, Bulla R, Salmon JE, Tedesco F (2006) The complement system in the pathophysiology of pregnancy. Mol Immunol 43:68–77PubMed
119.
Trundley A, Moffett A (2004) Human uterine leukocytes and pregnancy. Tissue Antigens 63:1–12PubMed
120.
Dosiou C, Giudice LC (2005) Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocr Rev 26:44–62PubMed
121.
Saito S, Morii T, Enomoto M, Sakakura S, Nishikawa K, Narita N, Ichijo M (1993) The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells. Cell Immunol 152:605–613PubMed
122.
Verma S, Hiby SE, Loke YW, King A (2000) Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15. Biol Reprod 62:959–968PubMed
123.
Guimond MJ, Luross JA, Wang B, Terhorst C, Danial S, Croy BA (1997) Absence of natural killer cells during murine pregnancy is associated with reproductive compromise in TgE26 mice. Biol Reprod 56:169–179PubMed
124.
Guimond MJ, Wang B, Croy BA (1998) Engraftment of bone marrow from severe combined immunodeficient (SCID) mice reverses the reproductive deficits in natural killer cell-deficient tg epsilon 26 mice. J Exp Med 187:217–223PubMed
125.
Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D (1991) Granulated lymphocytes in human endometrium: histochemical and immunohistochemical studies. Hum Reprod 6:791–798PubMed
126.
Avril T, Jarousseau AC, Watier H, Boucraut J, Le Bouteiller P, Bardos P, Thibault G (1999) Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism. J Immunol 162:5902–5909PubMed
127.
Saito S, Umekage H, Nishikawa K, Morii T, Narita N, Enomoto M, Sakakura S, Harada N, Ichijo M, Morikawa H (1996) Interleukin 4 (IL-4) blocks the IL-2-induced increased in natural killer activity and DNA synthesis of decidual CD16-CD56bright NK cells by inhibiting expression of the IL-2 receptor alpha, beta, and gamma. Cell Immunol 170:71–77PubMed
128.
McIntire RH, Hunt JS (2005) Antigen presenting cells and HLA-G-a review. Placenta 26 Suppl A:S104–S109PubMed
129.
Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73:209–212PubMed
130.
Duffield JS (2003) The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) 104:27–38CrossRef
131.
Starkey PM, Sargent IL, Redman CW (1988) Cell populations in human early pregnancy decidua: characterization and isolation of large granular lymphocytes by flow cytometry. Immunology 65:129–134PubMed
132.
Mor G, Abrahams VM (2003) Potential role of macrophages as immunoregulators of pregnancy. Reprod Biol Endocrinol 1:119PubMed
133.
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23–35PubMed
134.
Heikkinen J, Mottonen M, Komi J, Alanen A, Lassila O (2003) Phenotypic characterization of human decidual macrophages. Clin Exp Immunol 131:498–505PubMed
135.
Jones RL, Stoikos C, Findlay JK, Salamonsen LA (2006) TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 132:217–232PubMed
136.
Reister F, Frank HG, Kingdom JC, Heyl W, Kaufmann P, Rath W, Huppertz B (2001) Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women. Lab Invest 81:1143–1152PubMed
137.
Bowen JM, Chamley L, Mitchell MD, Keelan JA (2002) Cytokines of the placenta and extra-placental membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. Placenta 23:239–256PubMed
138.
Medawar PB (1953) Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol 7:320–338
Metadata
Title
The role of macrophage migration inhibitory factor in maintaining the immune privilege at the fetal–maternal interface
Authors
Paola Viganò
Marcella Cintorino
Frederick Schatz
Charles J. Lockwood
Felice Arcuri
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 2/2007
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-007-0074-3

Other articles of this Issue 2/2007

Seminars in Immunopathology 2/2007 Go to the issue

Review

Neuroendocrine–immune disequilibrium and endometriosis: an interdisciplinary approach

Review

UNK cells: their role in tissue re-modelling and preeclampsia

Review

The Th1/Th2 paradigm: still important in pregnancy?

Review

The feto–maternal interface: setting the stage for potential immune interactions

Introduction

Immunopathology of pregnancy and conception

Review

Antisperm antibodies and conception
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits